AURORA, Colo. – The CU Technology Transfer Office announced news of a patent granted to three researchers. They are School of Medicine researchers and CU Cancer Center members Richard Duke, Medical Oncology; Donald Bellgrau, Immunology, National Jewish; and Jerome Schaack , Microbiology.

This patent is for a method of treating cancer using viral vectors that express a protein which induces tumor cell death (apoptosis). This patent is part of a portfolio of intellectual property being commercialized by ApopLogic Pharmaceuticals, a company founded by Duke and other CU cancer researchers in 2005 to develop a variety of CU anti-cancer technologies. The company received a $100K proof-of-concept investment from CU to help move its programs forward.

The CU Tech Transfer Office began prosecuting this family of patents on behalf of the university in 1995; it includes several U.S. and foreign patents. U.S. 8,715,645 (“Viral Vectors Encoding Apoptosis-Inducing Proteins and Methods for Making and Using the Same”) was filed in April 2004 and issued on May 5, 2014.

Office of University Communications

CU Anschutz
Building 500

13001 East 17th Place

Room CG009

Aurora, CO 80045